Next Article in Journal
CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy
Next Article in Special Issue
Drosophila Homeodomain-Interacting Protein Kinase (Hipk) Phosphorylates the Homeodomain Proteins Homeobrain, Empty Spiracles, and Muscle Segment Homeobox
Previous Article in Journal
FK506 Induces Ligand-Independent Activation of the Bone Morphogenetic Protein Pathway and Osteogenesis
Previous Article in Special Issue
Thrombomodulin Regulation of Mitogen-Activated Protein Kinases
Article Menu

Export Article

Open AccessReview
Int. J. Mol. Sci. 2019, 20(8), 1901; https://doi.org/10.3390/ijms20081901

Targeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys”

1
Medical Oncology Department, The Ramón y Cajal Health Research Institute (IRYCIS), CIBERONC, Alcalá University, University Hospital Ramon y Cajal, 28034 Madrid, Spain
2
Biomarkers and Therapeutic Targets Group and Core Facility, Ramón y Cajal Research Institute, (IRYCIS), 28034 Madrid, Spain
3
Medical Oncology Department, MD Anderson Cancer Center, 28034 Madrid, Spain
4
Medical Oncology Department, Ramón y Cajal Health Research Institute (IRYCIS). CIBERONC, Alcalá University, University Hospital Ramon y Cajal, 28034 Madrid, Spain
*
Authors to whom correspondence should be addressed.
Received: 31 March 2019 / Revised: 14 April 2019 / Accepted: 15 April 2019 / Published: 17 April 2019
(This article belongs to the Special Issue Kinase Signal Transduction 2019)
  |  
PDF [740 KB, uploaded 17 April 2019]
  |  

Abstract

Clear cell renal cell carcinoma (ccRCC) is the seventh most frequently diagnosed tumor in adults in Europe and represents approximately 2.5% of cancer deaths. The molecular biology underlying renal cell carcinoma (RCC) development and progression has been a key milestone in the management of this type of tumor. The discovery of Von Hippel Lindau (VHL) gene alterations that arouse in 50% of ccRCC patients, leads the identification of an intracellular accumulation of HIF and, consequently an increase of VEGFR expression. This change in cell biology represents a new paradigm in the treatment of metastatic renal cancer by targeting angiogenesis. Currently, there are multiple therapeutic drugs available for advanced disease, including therapies against VEGFR with successful results in patients´ survival. Other tyrosine kinases’ pathways, including PDGFR, Axl or MET have emerged as key signaling pathways involved in RCC biology. Indeed, promising new drugs targeting those tyrosine kinases have exhibited outstanding efficacy. In this review we aim to present an overview of the central role of these tyrosine kinases’ activities in relevant biological processes for kidney cancer and their usefulness in RCC targeted therapy development. In the immunotherapy era, angiogenesis is still an “old guy” that the medical community is trying to fight using “new bullets”. View Full-Text
Keywords: Tyrosine kinase; Kidney cancer; Vascular endothelial growth factor receptor (VEGFR); Platelet Derived Growth Factor Receptor (PDGFR); Tyrosine-Protein Kinase Met (MET); Axl; Fibroblast Growth factor Receptor (FGFR) Tyrosine kinase; Kidney cancer; Vascular endothelial growth factor receptor (VEGFR); Platelet Derived Growth Factor Receptor (PDGFR); Tyrosine-Protein Kinase Met (MET); Axl; Fibroblast Growth factor Receptor (FGFR)
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Alonso-Gordoa, T.; García-Bermejo, M.L.; Grande, E.; Garrido, P.; Carrato, A.; Molina-Cerrillo, J. Targeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys”. Int. J. Mol. Sci. 2019, 20, 1901.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top